VanEck Biotech ETF (NASDAQ:BBH – Get Free Report) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totalling 700 shares, a growth of 75.0% from the September 15th total of 400 shares. Based on an average daily trading volume, of 5,200 shares, the short-interest ratio is currently 0.1 days.
VanEck Biotech ETF Price Performance
NASDAQ BBH traded up $2.37 during mid-day trading on Friday, reaching $177.93. 2,326 shares of the stock were exchanged, compared to its average volume of 6,921. The stock has a 50 day simple moving average of $178.10 and a 200-day simple moving average of $170.73. VanEck Biotech ETF has a one year low of $142.51 and a one year high of $183.64.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of BBH. Mather Group LLC. bought a new stake in VanEck Biotech ETF in the 2nd quarter worth $46,000. Red Lighthouse Investment Management LLC purchased a new stake in shares of VanEck Biotech ETF during the 2nd quarter valued at about $51,000. Hyman Charles D bought a new stake in shares of VanEck Biotech ETF in the second quarter worth $202,000. Truist Financial Corp grew its position in VanEck Biotech ETF by 3.8% during the second quarter. Truist Financial Corp now owns 2,703 shares of the company’s stock valued at $455,000 after buying an additional 100 shares during the period. Finally, Atlas Capital Advisors LLC purchased a new stake in shares of VanEck Biotech ETF in the 2nd quarter worth $960,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.
About VanEck Biotech ETF
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
Further Reading
- Five stocks we like better than VanEck Biotech ETF
- What is the Dow Jones Industrial Average (DJIA)?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- There Are Different Types of Stock To Invest In
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Retail Stocks Investing, Explained
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
